Dr. Charles Park Richardson

Distinguished Science and Technology Advisor

Global healthcare strategist joins CCQC

Dr. Charles Parks Richardson Appointed Distinguished Science & Technology Advisor to the Center for Computational Quantum Chemistry

Dr. Charles Parks Richardson has been appointed Distinguished Science and Technology Advisor to the Center for Computational Quantum Chemistry. He also serves as Executive Director of Clinical Innovation, Life Science Innovations & Biomedical Partnerships at American Heritage Schools, supporting both the Palm Beach and Broward campuses.

Dr. Richardson is leading a groundbreaking collaboration between the University of Georgia College of Public Health, the College of Pharmacy, and the Center for Computational Quantum Chemistry to advance next-generation healthcare innovation, drug discovery, and translational medicine.

A visionary physician, entrepreneur, and global healthcare strategist, Dr. Richardson is internationally recognized for his leadership in biopharmaceutical innovation, medical devices, and public health systems. His work bridges clinical medicine, advanced computing, artificial intelligence, and emerging quantum technologies to help accelerate the future of healthcare.

Throughout his career, Dr. Richardson has led transformative initiatives in therapeutic development, healthcare infrastructure, and medical technology innovation. He has advised on major healthcare acquisitions, pioneered life-saving cardiac technologies, and expanded healthcare access for underserved populations worldwide.

Among his key achievements:

  • Healthcare Innovation: Founder of Cleveland Heart, collaborating with Cleveland Clinic on next-generation cardiac circulatory assist devices, including left and right ventricular assist devices and a total implantable artificial heart.
  • SC411 Therapeutic Leadership: Led the clinical development strategy for SC411, advancing the program toward Phase 3 trials and global commercialization for sickle cell disease treatment.
  • AI, Quantum & Drug Discovery: Helping leverage AI, machine learning, and quantum-enabled computational platforms through the University of Georgia Quantum Hub to accelerate next-generation drug development.
  • Strategic Industry Impact: Contributed to strategic healthcare initiatives associated with the acquisition of Thoratec by St. Jude Medical ($3.4B) and Spark Therapeutics by Roche ($4.8B).
  • Global Health & Public Health Systems: Directed healthcare and pharmaceutical access initiatives across Africa, India, and the Middle East, including predictive drug inventory systems and public health programs supporting underserved communities.

In parallel with his broader healthcare and innovation activities, Dr. Richardson is also supporting the continued growth of biomedical engineering, clinical innovation, and experiential learning initiatives at American Heritage Schools’ Palm Beach and Broward campuses, helping foster interdisciplinary collaboration and real-world exposure for the next generation of healthcare and technology leaders.

Dr. Richardson is widely respected as a thought leader in healthcare innovation, disaster preparedness, translational medicine, and equitable access to therapeutics. His appointment further strengthens the growing collaboration between healthcare, artificial intelligence, quantum science, and biomedical education.